• FirefoxUpgrade to the new Firefox »
  •  Dow Up2.43% Nasdaq Up2.24%

    ProFunds Biotechnology UltraSector Inv (BIPIX)

    68.35 Up 3.30(5.07%) Dec 18

    Profile as of Nov 29, 2014Get Profile for:
    ProFunds Biotechnology UltraSector Inv
    Profunds3435 Stelzler RdColumbus, OH 43219
    Map
    Phone: 888-776-3637
    Fund Overview 
    Category:Trading-Leveraged Equity
    Fund Family:ProFunds
    Net Assets:703.49M
    Year-to-Date Return:50.74%
    Yield:0.00%
    Morningstar Rating:4 stars
    Fund Inception Date:Jun 19, 2000
    Morningstar Style Box 
    Trading-Leveraged Equity
    [View Category Definition]
    View Top Trading-Leveraged Equity Funds
    About the Morningstar Style Box
    Management Information 
    Michael Neches
    Lead Manager since Oct 1, 2013
    Michael Neches, ProShare Advisors—Portfolio Manager as of December 2009; Associate Portfolio Manager from January 2007 through November 2009; and Portfolio Analyst from November 2004 to December 2006. ProFund Advisors—Portfolio Manager as of December 2009.
    Investment Information 
    Min Initial Investment:15,000
    Min Initial Investment, IRA:15,000
    Min Initial Investment, AIP:15,000
    Min Subsequent Investment:N/A
    Min Subsequent Investment, IRA:N/A
    Min Subsequent Investment, AIP:N/A
    BIPIX can be purchased from 84 brokerages.

    Fund Summary 
    The investment seeks daily investment results, before fees and expenses, that correspond to one and one-half times (1.5x) the daily performance of the Dow Jones U.S. BiotechnologySM Index. The fund invests in securities and derivatives that the adviser believes, in combination, should have similar daily return characteristics as one and one-half times (1.5x) the daily return of the index. The index measures the performance of the biotechnology sector of the U.S. equity market. It is non-diversified.

    Fund Operations 
    Last Dividend : 0.00
    Last Cap Gain (Dec 14, 2014) : 0.00
    Annual Holdings Turnover (Dec 15, 2014) : 47.00%
    Average for Category:365.68%
    Fees & Expenses 
    ExpenseBIPIXCategory Avg
    Annual Report Expense Ratio (net):1.57%2.03%
    Prospectus Net Expense Ratio:1.57%N/A
    Prospectus Gross Expense Ratio:1.57%N/A
    Max 12b1 Fee:0.00%N/A
    Max Front End Sales Load:N/A4.75%
    Max Deferred Sales Load: N/A1.00%
    3 Yr Expense Projection*:496716
    5 Yr Expense Projection*:8551,194
    10 Yr Expense Projection*:1,8672,511
    * Per $10,000 invested